The development of targeted treatments for depression in bipolar disorder (BD-D) has lagged behind recognition of the prevalence and severity of this condition.1,2 All current medications have been borrowed from treatments for unipolar or major depression, mania, or maintenance treatment of bipolar disorder (BD). Despite many alternatives, few drugs have been tested. In addition, very few studies account for subtypes of illness, including BD type 1 vs BD type 2, mild vs severe depression, or new vs recurrent depression. Differences related to age, sex, or comorbid conditions are rarely addressed.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cohen BM. Evidence-Based Drug Treatment of Acute Depression in Bipolar Disorder. JAMA Psychiatry. 2019;76(12):1314–1315. doi:10.1001/jamapsychiatry.2019.3012
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: